Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6320894 | 0.97 | TDP1 (0.48) | TDP1 | |
| SCHEMBL647786 | 0.75 | — | — | |
| SCHEMBL8284502 | 0.75 | TDP1 (0.56) | TDP1 | |
| Potassium SCHEMBL29394450 | 0.73 | — | — | |
| SCHEMBL11137964 | 0.71 | TDP1 (0.50) | TDP1 | |
| SCHEMBL8900116 | 0.71 | TDP1 (0.50) | TDP1 | |
| SCHEMBL1128372 | 0.71 | TDP1 (0.50) | TDP1 | |
| SCHEMBL1148843 | 0.69 | TDP1 (0.40) | TDP1 | |
| Ammonia Solution, Strong SCHEMBL1014281 | 0.69 | TDP1 (0.48) | TDP1 | |
| Tert-Butyl Formate SCHEMBL1671 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 747 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| EP-3985008-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | Incyte Holdings Corporation (US) | 2022-04-20 | — | — | EP | claimed |
| EP-3053944-B1 | METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR | SHINETSU CHEMICAL CO (JP) | 2021-10-06 | — | — | EP | claimed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | claimed |
| EP-3398952-B1 | SYNTHESIS PROCESS OF RUXOLITINIB | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-07-14 | — | — | EP | claimed |
| EP-3473625-B1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-06-02 | — | — | EP | claimed |
| US-10766901-B2 | Preparation method for chiral pyrrolopyrimidine compound | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-08 | — | — | US | claimed |
| EP-3191479-B1 | \"PROCESS FOR THE PREPARATION OF MACROCYCLIC KETONE ANALOGS OF HALICHONDRIN B OR PHARMACEUTICALLY ACCEPTABLE SALTS AND INTERMEDIATES THEREOF\ | CIPLA LTD (IN) | 2020-04-08 | — | — | EP | claimed |
| US-10562904-B2 | Synthesis process of ruxolitinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-02-18 | — | — | US | claimed |
| US-20190211021-A1 | Preparation Method For Chiral Pyrrolopyrimidine Compound | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-07-11 | — | — | US | claimed |
| US-5011940-A | Process for the preparation of bicyclic amino carboxylic acids, intermediates in this process, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-04-30 | — | — | US | claimed |
| EP-0410278-A1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-30 | — | — | EP | claimed |
| EP-0394829-A1 | Renin-inhibiting dipeptides, process to synthetize them, compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-31 | — | — | EP | claimed |
| EP-0362634-A2 | Basic dihydropyridines, process for their preparation and their use as intermediates | BAYER AG (DE) | 1990-04-11 | — | — | EP | claimed |
| US-4857520-A | Fused azepinone and azocinone derivatives, processes for their preparation, agents containing them and their use, and intermediates in their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-15 | — | — | US | claimed |
| US-4855286-A | HYPOTENSIVE AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-08 | — | — | US | claimed |
| EP-0255082-A2 | Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-02-03 | — | — | EP | claimed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
| EP-0066103-B1 | PROCESS FOR THE REDUCTION OF REDUCIBLE GROUPS, AND ITS APPLICATION | Eckert, Heiner, dr. (DE) | 1985-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562904-B2 | Synthesis process of ruxolitinib | JAK3, JAK1, JAK2 | TDP1 4737/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | TDP1 2955/4885 |
| US-20190211021-A1 | Preparation Method For Chiral Pyrrolopyrimidine Compound | DHPS, DPYD, MPHOSPH6 | TDP1 3133/4885 |
| US-10766901-B2 | Preparation method for chiral pyrrolopyrimidine compound | DHPS, DPYD, MPHOSPH6 | TDP1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.